These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34170509)

  • 1. Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease.
    Ketteler M; Ambühl P
    J Nephrol; 2021 Oct; 34(5):1405-1418. PubMed ID: 34170509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release calcifediol in stage 3-4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D.
    Cozzolino M; Minghetti P; Navarra P
    J Nephrol; 2022 Apr; 35(3):863-873. PubMed ID: 34626363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Extended release calcifediol and paricalcitol in the treatment of secondary hyperparathyroidism: a network meta-analysis of indirect comparison].
    Franchi M; Galassi A; Corrao G
    G Ital Nefrol; 2023 Feb; 40(1):. PubMed ID: 36883925
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
    Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
    Joy MS; Karagiannis PC; Peyerl FW
    J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future.
    Brandenburg V; Ketteler M
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients.
    Germain MJ; Paul SK; Fadda G; Broumand V; Nguyen A; McGarvey NH; Gitlin MD; Bishop CW; Csomor P; Strugnell S; Ashfaq A
    BMC Nephrol; 2022 Nov; 23(1):362. PubMed ID: 36368937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
    Ennis JL; Worcester EM; Coe FL; Sprague SM
    J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis.
    Franchi M; Gunnarsson J; Gonzales-Parra E; Ferreira A; Ström O; Corrao G
    J Clin Endocrinol Metab; 2023 Oct; 108(11):e1424-e1432. PubMed ID: 37235771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency.
    Galassi A; Ciceri P; Porata G; Iatrino R; Boni Brivio G; Fasulo E; Magagnoli L; Stucchi A; Frittoli M; Cara A; Cozzolino M
    Expert Opin Drug Saf; 2021 Nov; 20(11):1333-1349. PubMed ID: 33993809
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s.
    Ketteler M; Bover J; Mazzaferro S
    Nephrol Dial Transplant; 2023 May; 38(6):1397-1404. PubMed ID: 35977397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease.
    Galassi A; Bellasi A; Ciceri P; Pivari F; Conte F; Cozzolino M
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1073-1084. PubMed ID: 28846459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Cozzolino M; Ketteler M
    Expert Opin Pharmacother; 2019 Dec; 20(17):2081-2093. PubMed ID: 31675257
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease.
    Sprague SM; Crawford PW; Melnick JZ; Strugnell SA; Ali S; Mangoo-Karim R; Lee S; Petkovich PM; Bishop CW
    Am J Nephrol; 2016; 44(4):316-325. PubMed ID: 27676085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease.
    Sprague SM; Silva AL; Al-Saghir F; Damle R; Tabash SP; Petkovich M; Messner EJ; White JA; Melnick JZ; Bishop CW
    Am J Nephrol; 2014; 40(6):535-45. PubMed ID: 25572630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
    Warady BA; Ng E; Bloss L; Mo M; Schaefer F; Bacchetta J
    Pediatr Nephrol; 2020 Sep; 35(9):1679-1697. PubMed ID: 32367309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial.
    Thimachai P; Supasyndh O; Chaiprasert A; Satirapoj B
    J Med Assoc Thai; 2015 Jul; 98(7):643-8. PubMed ID: 26267985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.